GLGerald Lip

Gerald Lip

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gerald Lip has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Artificial Intelligence in Breast Imaging and Screening: Current Evidence, Applications, and Future Directions

    by Amrita Kumar, Gerald Lip

    Artificial intelligence (AI) has emerged as a clinically significant and rapidly evolving technology in breast imaging, with applications spanning cancer detection, risk prediction, workflow optimization, and supplemental imaging modalities. The evidence base has matured rapidly, transitioning from retrospective accuracy studies to prospective randomized controlled trials. This narrative review synthesizes the most recent evidence (2023–2026) on AI applications in breast cancer screening and imaging, including landmark trial results, systematic reviews, and society recommendations. Current data demonstrate that AI-supported mammography screening can increase cancer detection rates by 10 to 29% and reduce interval cancer rates by up to 12% while reducing radiologist workload by 31 to 64% in double-reading screening settings, without increasing false-positive rates. However, the evidence base remains predominantly derived from nondiverse, high-income country populations, and long-term outcome data including breast cancer mortality are not yet available. Challenges related to generalizability, algorithmic bias, overdiagnosis, and regulatory frameworks remain. As the field moves toward clinical implementation, rigorous post-market surveillance, diverse dataset validation, and cost-effectiveness analyses will be essential.

  • Postdeployment Monitoring and Surveillance Methods, Guidelines, and Possibilities for AI in Radiology

    by Vasantha Kumar Venugopal, Suyash Anil Khubchandani, Charlene Jin Yee Liew, Felipe Campos Kitamura, Rohit Takhar, Gerald Lip

    Radiology is increasingly adopting AI systems, and to ensure their safety after the systems go live, postdeployment monitoring is essential as part of the total product life cycle framework.


  • Top Cited Papers
    Open Access

    Prospective evaluation of artificial intelligence integration into breast cancer screening in multiple workflow settings: the GEMINI study

    by Clarisse Florence de Vries, Gerald Lip, Roger Todd Staff, Jaroslaw Artur Dymiter, Benjamin Tse, Annie Ng, Georgia Fox, Cary Oberije, Lesley Ann Anderson

    Artificial intelligence (AI) tools can improve breast screening performance but different screening sites have varying needs. Here the GEMINI prospective evaluation of 10,889 women, within one UK region, used both live AI integration and simulations to model 17 different ways AI could be used in breast screening. All women received routine care. One AI tool was assessed. When the AI tool recommended recall but routine double reading did not, cases underwent additional human review, detecting 11 additional cancers. The primary AI workflow could improve cancer detection by 10.4% (1 per 1,000), maintain the recall rate (0.8% reduction) and reduce workload by up to 31%. Other workflow variations significantly improved all measured metrics (superiority in cancer detection rate, recall rate, positive predictive value (PPV), sensitivity and specificity) with up to 36% workload savings. Different AI integrations in breast screening could offer various clinical and operational gains, allowing for adaptation to local healthcare needs.


  • Open Access

    A compendium of adipocyte morphologies across different breast pathologies

    by Abigail Dodson, Katie Hanna, Kerri Palmer, Hafeez Ibrahim, Katharina Kusserow, Rasha Abu-Eid, Gerald Lip, Nicola Spence, Ehab Husain, Beatrix Elsberger, et al.

    Adipocytes are abundant in the breast tissue microenvironment. In breast cancer, they can change morphologically according to their proximity to tumour cells, with the closest becoming cancer-associated adipocytes (CAAs). It remains unclear whether breast cancer risk factors, including menopausal status, body mass index (BMI), and mammographic density (MD), influence CAAs morphology in breast carcinogenesis. This study aimed to quantify morphological differences in adipocytes across breast cancer pathologies and associated risk factors. Whole slide images of haematoxylin and eosin stained cancer (n = 149) and normal (n = 182) breast tissue samples were analysed. Parameters representative of adipocyte morphology: perimeter, area, concavity, and aspect ratio, were measured using ImageJ. Adipocytes were considered close (≤2 mm) or distant ( > 2 mm) to cancer cells in cancer samples or breast epithelial cells in normal samples. Close adipocytes in cancer samples were designated CAAs. CAAs decreased in size compared to distant adipocytes (p≤0.0001). A similar trend was observed between close and distant adipocytes in normal (p≤0.0001). CAAs size increased post menopause (p ≤ 0.0001). CAAs size positively correlated with BMI (p ≤ 0.0001). In cancer cases, distant adipocyte size increased and concavity decreased with increasing MD (p ≤ 0.01). Smaller CAAs were associated with poorer survival (p≤0.05). Morphological differences were identified in adipocytes dependent on location within the breast, tissue, pathology and risk factors. Understanding what drives these morphological differences could provide mechanistic insight into whether risk factor-induced alterations in adipocytes influence their role in breast carcinogenesis.


  • Open Access

    A compendium of adipocyte morphologies across different breast pathologies

    by Abigail Dodson, Katie Hanna, Kerri Palmer, Hafeez Ibrahim, Rasha Abu-Eid, Gerald Lip, Nicola Spence, Ehab Husain, Beatrix Elsberger, Justin J. Rochford, et al.

    Adipocytes are abundant in the breast tissue microenvironment. In breast cancer, they can change morphologically according to their proximity to tumour cells, with the closest becoming cancer-associated adipocytes (CAAs). It remains unclear whether breast cancer risk factors, including menopausal status, body mass index (BMI), and mammographic density (MD), influence CAAs morphology in breast carcinogenesis. This study aimed to quantify morphological differences in adipocytes across breast cancer pathologies and associated risk factors. Whole slide images of hematoxylin and eosin stained cancer ( n = 149) and normal ( n = 182) breast tissue samples were analysed. Parameters representative of adipocyte morphology: perimeter, area, concavity, and aspect ratio, were measured using ImageJ. Adipocytes were considered close (≤ 2 mm) or distant (>2 mm) to cancer cells in cancer samples or breast epithelial cells in normal samples. Close adipocytes in cancer samples were designated CAAs. CAAs decreased in size compared to distant adipocytes ( p ≤ 0.0001). A similar trend was observed between close and distant adipocytes in normal ( p ≤ 0.0001). CAAs size increased post menopause ( p ≤ 0.0001). CAAs size positively correlated with BMI ( p ≤ 0.0001). In cancer cases, distant adipocyte size increased and concavity decreased with increasing MD ( p ≤ 0.01). Smaller CAAs were associated with poorer survival ( p ≤ 0.05). Morphological differences were identified in adipocytes dependent on location within the breast, tissue, pathology and risk factors. Understanding what drives these morphological differences could provide mechanistic insight into whether risk factor-induced alterations in adipocytes influence their role in breast carcinogenesis.

  • Non-biopsy of fibroadenomas in the UK and Ireland: a British Society of Breast Radiology survey of national practice

    by S. Lowes, E. Gibson, T. Kulkarni, J. Nash, N. Sharma, S. Sharma, T. Suaris, M. Telesca, G. Lip, N. Healy


  • Open Access

    Field cycling imaging to characterise breast cancer at low and ultra-low magnetic fields below 0.2 T

    by Vasiliki Mallikourti, P. James Ross, Oliver Maier, Katie Hanna, Ehab Husain, Gareth R. Davies, David J. Lurie, Gerald Lip, Hana Lahrech, Yazan Masannat, et al.

    Background: This prospective feasibility study explores Field-Cycling Imaging (FCI), a new MRI technology that measures the longitudinal relaxation time across a range of low magnetic field strengths, providing additional information about the molecular properties of tissues. This study aims to assess the performance of FCI and investigate new quantitative biomarkers at low fields within the context of breast cancer. Methods: We conducted a study involving 9 people living with breast cancer (10 tumours in total, mean age, 54 ± 10 years). FCI images were obtained at four magnetic field strengths (2.3 mT to 200 mT). FCI images were processed to generate T1 maps and 1/T1 dispersion profiles from regions of tumour, normal adipose tissue, and glandular tissue. The dispersion profiles were subsequently fitted using a power law model. Statistical analysis focused on comparing potential FCI biomarkers using a Mann-Whitney U or Wilcoxon signed rank test. Results: We show that low magnetic fields clearly differentiate tumours from adipose and glandular tissues without contrast agents, particularly at 22 mT (1/T1, median [IQR]: 6.8 [3.9–7.8] s−1 vs 9.1 [8.9–10.2] s−1 vs 8.1 [6.2–9.2] s−1, P < 0.01), where the tumour-to-background contrast ratio was highest (62%). Additionally, 1/T1 dispersion indicated a potential to discriminate invasive from non-invasive cancers (median [IQR]: 0.05 [0.03–0.09] vs 0.19 [0.09–0.26], P = 0.038). Conclusions: To the best of our knowledge, we described the first application of in vivo FCI in breast cancer, demonstrating relevant biomarkers that could complement diagnosis of current imaging modalities, non-invasively and without contrast agents.


  • Residual microcalcifications after neoadjuvant systemic therapy for early breast cancer: Implications for surgical planning and long-term outcomes

    by Joel Allotey, Vinita Ruparel, Anna McCallum, Karendeep Somal, Louise Simpson, Gaurav Gupta, Gerald Lip, Ravi Sharma, Yazan Masannat


  • Open Access

    Field Cycling Imaging: a novel modality to characterise breast cancer at low and ultra-low magnetic fields below 0.2T

    by Vasiliki Mallikourti, Peter Ross, Oliver Maier, Katie Hanna, Ehab Hussein, Gareth Davies, David Lurie, Gerald Lip, Hana Lahrech, Yazan Masannat, et al.

    We propose Field-Cycling Imaging (FCI), a new MRI technology accessing a range of low and ultra-low magnetic fields (2mT to 0.2T), to acquire longitudinal relaxation time over 4 orders of magnitude of field strength, and covering the whole body. FCI obtains the Nuclear Magnetic Relaxation Dispersion (NMRD) profiles of tissues, which probes molecular dynamics at micro- to nanometer scales. We present a prospective study including 10 female patients with breast cancers. Low magnetic fields clearly differentiate tumours from adipose and glandular tissues and discriminates true tumour extent beyond that of conventional imaging, matching the true pathological size of the lesion. Using our FCI prototype, T1 variations at low and ultra-low field discriminate invasive from non-invasive cancers in patients (p < 0.05). To our knowledge, we described the first application of in vivo FCI in breast cancer, demonstrating relevant biomarkers that complement diagnosis of current imaging modalities, non-invasively and without contrast agents.

  • Open Access

    Adoption, orchestration, and deployment of artificial intelligence within the National Health Service—facilitators and barriers: an expert roundtable discussion

    by Gerald Lip, Alex Novak, Mathias Goyen, Katherine Boylan, Amrita Kumar

    Clinical care, workflow, and patient outcomes within National Health Service (NHS) radiology services will potentially benefit significantly in coming years with the integration of artificial intelligence (AI) into various specialty areas. This article summarizes an expert roundtable discussion, convened by the British Institute of Radiology, comprised experts from clinical, NHS management and industry backgrounds. Facilitators and barriers to both implementation and integration of AI platforms into daily practice are discussed alongside examples including AI in emergency care and breast screening. Issues addressed include the need to generate more real-world evidence that helps developers and service providers to determine the optimal way for patients to reap the benefits of AI with faster reporting turnaround time, faster diagnoses, and treatment times, for example. To ensure the effective and timely wide-scale implementation, adoption requires a national policy drive and national level coordination but specific, local needs of NHS Trusts and any particular service within Trusts will also need to be met. By embedding AI-capabilities into scanners, ultrasound-devices, X-ray equipment, and Picture archiving and communication system (PACS), local services will benefit, while AI applications can streamline workflows across and between departments and potentially Trusts. AI predictive analytics and systems engineering can be used to better manage patient volume and movement. In the short term, education, training, and confidence in adapting and adopting AI in radiology require dedicated local, national, and governmental effort but the future benefits promise to justify the means.